Investigational drug · Phase 3
XTR006
Also called: [18F]MK 6240, Florquinitau
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer Disease, Neurofibrillary Tangle.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "XTR006"
First trial start
2024
Nov 20, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XTR006", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
- Neurofibrillary Tangle
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "XTR006" as an intervention, largest first.
- Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and ADPivotal-lookingRecruiting
Sinotau Pharmaceutical GroupIndustry
NCT07115238 · 354 participants (planned) · Start Nov 20, 2024 · Primary completion Dec 31, 2025
Drug: XTR006 · For: Alzheimer Disease; Neurofibrillary Tangle
Sites: Beijing, China
Sinotau Pharmaceutical GroupIndustry
NCT06151808 · 42 participants · Start Sep 1, 2022 · Primary completion Nov 28, 2023
Drug: XTR006 · For: Alzheimer Disease
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- 18F-Florquinitau PET for imaging tau pathology in Alzheimer's disease.
Zhao T, Levey AI, Liang SH · Trends Pharmacol Sci 2026
- A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease.
Ruppert E, Vermeiren MR, Scop Medeiros M, et al. · JAMA Neurol 2026
- Evaluating early vs. late static SUVR windows of [¹ࠞF]MK-6240 tau PET in Alzheimer disease: a head-to-head comparison study.
Hu TW, Prince J, Zhou L, et al. · Eur J Nucl Med Mol Imaging 2026
- Tau positron emission tomography analysis methods for the quantification of tau spread in preclinical and early Alzheimer's disease.
Wong J, Wang T, Datta R, et al. · Alzheimers Dement 2026
- Longitudinal Evaluation of 18F-MK-6240 Along the Alzheimer Disease Continuum.
Giarratana AO, Jonaitis E, Przybelski RJ, et al. · J Nucl Med 2026
- In Vivo [18F]MK6240 PET Reveals Atypical Patterns of Early Tau Deposition and Evidence for Primary Age-Related Tauopathy in Community-Residing Adults.
Jaswal S, Ghaderi Yazdi B, Khalafi M, et al. · AJNR Am J Neuroradiol 2026
Also in development for Alzheimer Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- AR1001Phase 31 trial
AriBio Co., Ltd. · Alzheimer Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.